Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did not approve its lead investigational product, Cardamyst. The nasal spray ...

Shares of MIST plunged 66.2% since the CRL issuance, reflecting the delay in the launch of Cardamyst. The company’s shares have lost 67.8% so far this year against the industry’s 2.2% growth.

The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...

Joe Oliveto, President and CEO of Milestone Pharmaceuticals, expressed disappointment over the CRL but reaffirmed the company’s commitment to CARDAMYST as a potential novel treatment for ...

“2025 is set to be a transformative year for Milestone as we prepare for potential FDA approval of CARDAMYST and the opportunity to empower patients suffering with PSVT to self-manage episodes ...

Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray ...

"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided ...